Incorporating Glucagon-Like Peptide-1 Receptor Agonists in the Individualized Management of Patients with Type 2 Diabetes

Statement of Need/Program Overview

Clinicians, at the forefront of primary care, need to be up to date on the pharmacology of newer GLP-1 RAs, how to distinguish among available and emerging agents within the class, which patients will most benefit from GLP-1 RAs, and how to best incorporate them into patient management plans.
Learning Objectives

Upon proper completion of this activity, participants should be better able to:

Describe the mechanisms of action by which current and emerging GLP-1 RAs exert beneficial glycemic and extraglycemic effects on patients with T2D.
Match current and emerging GLP-1 RAs with appropriate patients based on unique agent characteristics (eg, dosing strategies, efficacy, and safety), current guideline recommendations, patient clinical characteristics, and patient preferences.
Describe clinician–patient communication strategies for promoting patient adherence to T2D treatment plans that include injectable therapies.